This CME activity is sponsored by Med Learning Group. This CNE activity is sponsored by Ultimate Medical Academy/CCM.
This activity is supported by an educational grant from Eli Lilly & Company
Release date: December 10, 2013
Valid through: October 31, 2014
This activity is designed to meet the educational needs of endocrinologists, primary care physicians, nurses, pharmacists, and other healthcare practitioners caring for diabetes patients.
Understanding the physiology of incretins; the pharmacokinetics differences between incretin-based therapies; their effects on FPG, PPG and bodyweight; and the efficacy and safety profile of these agents are all of fundamental importance to target glycemic disturbances. By targeting these specific areas, we can offer more individualized therapy for T2DM patients in order to improve glycemic control and delay disease progression.
Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab. 2012 Aug;14(8):675-88.